newsfilter
← Latest News
Business Wire·

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Phase 1 combination data of 6.5mg/m2 Q2W nuzefatide pevedotin plus nivolumab demonstrate an encouraging preliminary efficacy profile with a differentiated tolerability profile in previously treated metastatic urothelial